Company Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
The company’s products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea.
The company is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Lisa Conte |
Contact Details
Address: 200 Pine Street, Suite 400 San Francisco, California 94104 United States | |
| Phone | 415 371 8300 |
| Website | jaguar.health |
Stock Details
| Ticker Symbol | JAGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001585608 |
| CUSIP Number | 47010C805 |
| ISIN Number | US47010C8055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lisa A. Conte | Founder, Chief Executive Officer, President and Director |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer and Chair of Scientific Advisory Board |
| Jonathan S. Wolin C.P.A., J.D., M.B.A. | Chief of Staff, Chief Compliance Officer and General Counsel |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary |
| Carol R. Lizak M.B.A. | Chief Financial Officer and Chief Accounting Officer |
| Peter Hodge | Senior Director of Investor Relations, Business Development and Special Events |
| Dr. Karen J. Brunke Ph.D. | Executive Vice President of Corporate and Business Development |
| David Sesin Ph.D. | Chief Manufacturing Officer |
| Ian H. Wendt M.B.A. | Chief Commercial Officer |
| Dr. Massimo Radaelli M.B.A., Ph.D. | President of Jaguar International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | 8-K | Current Report |
| Apr 15, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 15, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 15, 2025 | 10-K/A | [Amend] Annual report |
| Apr 4, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |